Significant Advances in ARV Formulations are Still Limited by Poor Adherence

Since the advent of zidovudine (AZT) to treat HIV infection over twenty-seven years ago, the number of available therapeutic choices has grown to include dozens of antiretroviral drugs (ARVs) spanning five therapeutic categories [1]. The global scale-up of antiretroviral therapy is the combined achievement of scientists, clinicians, patients, advocates and pharmaceutical industry [2-4]. These ARVs not only improve life quality and expectancy, but also prevent perinatal and horizontal transmission of HIV infection. Alongside advances in development and approval of ARVs, the availability of these drugs in low- and middle-income countries continues to improve. Despite the progress that has been made in improving access to ARVs, adherence to the treatment drug regimens, like in other chronic disease, remains a complex challenge [5-7]. Behavioral constraints limiting long-term adherence to medications treating a variety of chronic diseases are well documented [8-13]. Worldwide, low rates of adherence to ARV regimens combined with treatment interruptions continue to limit the effectiveness of HIV programs in reaching epidemic control. The combination of non-adherence and treatment interruptions leads to suboptimal community viral suppression, increased HIV spread, higher rates of morbidity and mortality and HIV drug resistance. Such resistance in turn requires increased use of more expensive second line drugs [14,15]. Similarly, the efficacy and safety of pre-exposure prophylaxis, a key tool to reduce the incidence of HIV infection in high-risk individuals, has been shown to be compromised by inconsistent dosing, leading to increases HIV transmission and resistance in the presence of sub-therapeutic drug levels [11,12,15].

The Promise of Drug Simplification

Due to these factors, non-adherence to ART remains among the most formidable obstacles to an AIDS-free generation. To minimize the liability that non-adherence represents and to lower the burden on patients on treatment, there remains a focus on simpler drugs that can be taken less often [16,17]. Simplified strategies have been demonstrated to improve adherence and patient satisfaction in other chronic disease management schema, including cardiovascular disease, hypertension, elevated cholesterol, thrombosis, depression, and osteoporosis [18-33]. In recent decades, increasingly simplified contraception methods has brought with them higher efficacy and patient convenience [34].

Simplifying ARVs

In the current context of HIV, the recommended first-line ART can be prescribed as a once-daily single fixed dose combination (FDC) tablet, representing a significant improvement in the pill burden and cost compared to previously available regimens (Table 1). Consistent with adherence studies across other chronic diseases, studies in the context of HIV suggest significant benefits to adherence and quality of life with simplified, once daily regimens as compared with twice daily, multi-pill regimens [35].

An effort to further widen the allowable time between ARV doses has led to the development of extended release oral formulations. The only currently available drug in this category is nevirapine XR, which was approved by the FDA in March 2011. The so-called VER×VE and TRAN×TION clinical trials established the clinical non-inferiority of NVP XR in both treatment-naïve and treatment-experienced patients [36,37]. Since approval, extended release nevirapine has been demonstrated to improve adherence, patient satisfaction and reduce the risk of resistance and virologic failure. Additionally, it has been shown to increase efficacy and decrease the incidence and intensity of adverse effects [38,39].

However, despite ARV simplification and a diversity of related strategies to reinforce day-to-day ARV adherence behaviors (directly

### Table 1: Differences Between the Price and Daily Pill Burden Between the First Line Regimen in 2002 and that from 2013.

<table>
<thead>
<tr>
<th>Regimen</th>
<th>2002</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-Line Regimen for Adults</td>
<td>AZT/3TC with NVP or EFV</td>
<td>TDF/FTC/EFV or TDF/3TC/EFV</td>
</tr>
<tr>
<td>Minimum Daily Pill Burden</td>
<td>3 tablets</td>
<td>1 tablet</td>
</tr>
<tr>
<td>Monthly Price for Minimum Pill Burden</td>
<td>$32.28</td>
<td>$11.38</td>
</tr>
</tbody>
</table>
observed therapy, treatment buddies, support groups, electronic reminder systems, etc.), adherence rates to daily regimens are inherently limited by predictable human behavior [40,41]. To boost lasting adherence, it is necessary to recognize this stubborn fact, and further simplify ARV regimens. The next logical step toward simpler, easier HIV therapy is the development of effective, affordable longer acting ARVs. In the absence of an HIV cure, we believe such ARVs, in the form of long-acting injectable (LAI) formulations, will define the future of life-long HIV management.

Long-Acting Injectibles (LAIs)

While the precedent for long-acting injectables in chronic disease management is limited, several key successes stand out. Use of long acting injectable antipsychotics for the treatment of schizophrenia have led to decreased hospitalization rates, improved adherence, treatment outcomes, patient satisfaction and better quality of life [21, 24,30,41-44]. The use of long-acting injectable glucagon-like peptide-1 receptor (GLP-1R) agonists for the treatment of diabetes has been shown to improve glycemic control, glycolated hemoglobin, promote weight loss as well as reduce cardiovascular risk by improving blood pressure control and lipid levels [45-47]. Injectable hormones have become the mainstay of long-acting contraception, decreasing unintended pregnancies and abortions while achieving lower failure rates in both resourced and under resourced countries [34,49,50].

Advantages of LAIs

The critical advantage to LAIs, of course, is that they could be dosed on a weekly, monthly, or multi-month schedule. Compared to oral dosing, LAIs would likely have reduced drug interactions related to first-pass metabolism, as well as decreased gastrointestinal toxicity [50]. Also, injectable formulations with specific target cells such as CD8 cells would require lower doses, potentially reducing costs of ARVs in resource limited settings where the active pharmaceutical ingredient compound represents a large proportion of the total production costs [50,51]. The availability of long acting parental ART formulations would benefit critically ill, hospitalized and perioperative patients who are unable to tolerate oral medications. Among populations that are particularly at risk for ARV non-adherence, LAIs would provide another option for healthcare providers who might be reluctant to prescribe oral ARVs due to anticipated adherence concerns [52]. Though previous studies have demonstrated that once-daily FDC is associated with improved adherence, it will be important to conduct behavioral studies to demonstrate this.

Predictable Challenges/Disadvantages of LAIs

As stated above, LAI formulations typically have a longer time (several days rather than hours) to maximum concentration \(T_{\text{max}}\) when compared of oral formulations, followed by sustained plasma concentration near peak concentrations \(C_{\text{peak}}\) [53-55]. For this reason, then starting a LAI, a period of oral induction therapy is often required help ensure achievement of appropriate drug concentrations while the LAI approaches \(T_{\text{max}}\). Oral induction also helps scout for hypersensitivity or drug toxicity, so that long-lasting adverse events might be avoided. Also, the prolonged clearance time of LAIs increase the risk of prolonged low drug concentrations in the context of missed doses. In sum, LAIs are likely to decrease adherence burden, but also raise the stakes in regards to adverse events and non-adherence. Please refer to Table 2 which describes additional challenges.

A Proof of Concept: Promising ARV LAIs in Clinical Development

Currently, two LAI ARV formulations – long-acting (LA) versions of a second generation non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine, and an integrase inhibitor, cabotegravir (formerly GSK744) – are in clinical-stage development. Both formulations are intended to be given monthly (or less frequently) and have been prepared using nanomilling technology. This nanomilling technology approach has already been already successfully applied to several FDA approved pharmaceutical formulations for other diseases, including: abraxane for the treatment of breast, pancreatic and small lung cell lung cancer; and doxil for the treatment of multiple myeloma and ovarian cancer [53-55].

Additionally, researchers are laying the ground work for assessment of combination LA ARVs for use as a maintenance regimen. Phase 2b of the Long-Acting Antiretroviral Treatment Enabling (LATTE) trial is currently evaluating oral cabotegravir plus rilpivirine as a 2-drug maintenance regimen among patients who have already achieved

<table>
<thead>
<tr>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved adherence</td>
<td>Pain, erythema, nodule formation at site injection</td>
</tr>
<tr>
<td>Decrease in pill intake exhaustion</td>
<td></td>
</tr>
<tr>
<td>Improved consistency in drug intake</td>
<td></td>
</tr>
<tr>
<td>Decrease in virologic failure</td>
<td></td>
</tr>
<tr>
<td>Reduced hepatic, GI and renal toxicity from first pass metabolism</td>
<td>Need for competent injection technique and for trained health care workers</td>
</tr>
<tr>
<td>Early detection of non-adherence with lower rates of virologic failure</td>
<td>Long periods of low drug concentration if injection is missed, likely leading to high risk of resistance</td>
</tr>
<tr>
<td>Reduced uncertainty about adherence to cART</td>
<td>Longer time to maximum concentration (can be dealt with oral lead in period)</td>
</tr>
<tr>
<td>Improved bioavailability</td>
<td>Potential for development of resistance when doses are missed</td>
</tr>
<tr>
<td>Decreased overall drug exposure</td>
<td>Difficulty with withdrawal of drug in the event of toxicity</td>
</tr>
<tr>
<td>Lower dose API are typically more suitable for , which could lead to potentially reduced costs of ARVs in resource limited settings</td>
<td>Need for increased clinic visits with monthly injections versus quarterly visits for stable ART patients on oral medications</td>
</tr>
<tr>
<td>Increased patient confidentiality in situations where stigma or discrimination might exist</td>
<td>Improved cost with lesser need for active ingredient</td>
</tr>
<tr>
<td>Can be considered for PreP use</td>
<td>Use as a PreP option could potentially lead to resistance given subtherapeutic levels if HIV is acquired</td>
</tr>
<tr>
<td>Nanoemulsions can be injected with reduced volume</td>
<td>Manufacturing of antibodies can be costly</td>
</tr>
<tr>
<td>Possibility for painful subcutaneous or subdermal implantation</td>
<td>Missing a dose may lead to longer coverage-free periods compared to oral doses</td>
</tr>
<tr>
<td>Much shorter tail of drug exposure in cases where loss-to-follow-up occurs</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Advantages and Disadvantages of Long-Acting Arvs.
viral suppression [56]. The LATTE trial has demonstrated that both drugs, when administered orally, were as effective and better tolerated in comparison to triple ART regimen containing efavirenz plus two NRTIs. Once these studies looking at the effectiveness and tolerability of the oral two-drug combination are complete, the researchers aim in subsequent studies to do a similar assessment with the LAI versions of the drugs [57].

When looking at the LAI plasma drug concentrations, a study conducted by Spreen et al. demonstrated that plasma drug concentrations achieved with the oral formulations were also achievable with an LAI formulation [58]. Following respective loading doses, cabotegravir consistently maintained high plasma concentrations (4-fold above the protein-adjusted inhibitory concentration (IC)-90 and comparable to steady-state oral RPV 25 mg/d) associated with monthly injections or quarterly intramuscular injections. For over 30 days, a 600-900mg dose of rilpivirine LAI maintained plasma concentrations above the plasma trough levels observed with 25mg daily oral rilpivirine.

Rilpivirine and cabotegravir represent a promising LAI combination for several reasons. Firstly, they appear to have good tolerability profiles; co-administration of these two ARV Nano suspensions was found to be safe and well tolerated in healthy human adults [59]. Secondly, cabotegravir has significantly higher resistance barrier than rilpivirine, and resulting resistance mutations confer low-level resistance without cross resistance to other integrate inhibitors. A tail containing cabotegravir LAI therefore offers some protection against the emergence of high-level resistance. Thirdly, the cost of producing this rilpivirine/cabotegravir combination is likely to be relatively affordable. Based on previous manufacturing estimates, rilpvirine LA and a theoretical formulation of dolutegravir LA (an integrase inhibitor similar to cabotegravir) would cost approximately $40 per year [35].

Proceeding With Caution: Moving Rilpivirine and Cabotegravir Toward Regulatory Approval

Though a combination LAI containing rilpivirine and cabotegravir provides the first proof-of-concept that LAIs can become a safe and effective alternative to oral regimens, this is just the beginning. The tolerability of this first generation combination LAI is limited by a relatively high (1-4 ml) injection volume, which can be painful when administered intramuscularly. The rilpivirine/cabotegravir formulation has a very long tail of drug exposure in the body (lasting up to a year) and therefore brings with it a high likelihood that resistance will develop in those lost to follow-up. As such an example, one case of rilpivirine-induced NNRTI resistance has already been reported in an initially HIV-uninfected trial participant who received rilpivirine LA for pre-exposure prophylaxis. The individual was then found to be infected months later, during the tail period [60]. Finally, while the manufacture costs of these two LAIs ARV's might be less than cost of currently recommended oral first line, other costs may increase the true costs the Nano milling process, injection equipment, and costs to the health system (training, personnel, gloves, etc.).

Conclusion
Looking ahead at the future of ARVs

Daily HIV treatment regimens remain an irrefutable and arguably insurmountable barrier to adherence and, ultimately, viral suppression and epidemic control. We must therefore identify strategies to ensure that we adequately target these barriers. As a rilpivirine/cabotegravir LAI moves toward regulatory approval, it is important to ask several critical questions.

1) How do we nurture further LAI development?

If ARV LAI regimens are to be truly transformative, their development needs to be prioritized. Significant improvements beyond first-generation ARV LAI combinations will be needed, and LAI development should be incentivized, including support of LAI cost-effectiveness studies.

2) Are there other ARVs that hold promise for inclusion in LAIs?

Prioritization of appropriate drugs for LAI development will require thoughtful planning. Stakeholders should invest in a long-term, concerted effort to carefully select promising pharmaceutical ingredients and design optimal drug delivery systems. For example, cabotegravir's many promising characteristics may lead to the selection of a compatible, efficacious partner drug for future LAI combinations. This partner drug would need to possess high potency and be concentrated in a much lower injection volume. It would need a high resistance barrier and tolerability along with a limited number of interactions with medications commonly utilized in resource-limited settings, including antimalarial, TB drugs and opportunistic infection prophylaxis.

3) How and where might we pilot ARV LAI implementation?

Assessments of LAIs are needed in both resource limited and resourced settings. Implementation of the first generation of LAIs in resource limited settings, even on a relatively small scale, would provide important lessons and inform good practices and approaches for improving development of subsequent generations of LAIs. Now is the time to consider how to design this pilot, with a focus on populations that typically experience high rates of poor adherence, ideally in high-burden, lower resourced settings. A pilot is also needed in resourced settings, perhaps targeting populations that are known for adherence issues and that would most benefit from LAIs, such as injection drug users [52].

4) Beyond LAIs, what long-acting approaches show promise?

LAI nanoemulsions, though poised to play a critical role in the further simplification of HIV treatment, are best suited to deliver hydrophobic compounds [62,63]. An alternative to injection is a transcutaneous delivery using a thin film biodegradable device made with the FDA-approved polymer called poly caprolactone, which can hold solid formulations of active pharmaceutical ingredients, and can be applied directly to skin [63]. Potential advantages of this approach include reduced drug volume, avoidance of painful injection, potential for longer-term activity, and a shorter tail of drug exposure in cases where loss-to-follow-up occurs.

5) What about broadly neutralizing antibodies?

Finally, broadly neutralizing antibodies (bnAbs) against HIV represent another promising area. Custom-engineered bnAbs hold immense promise and, high manufacturing costs, remain an active area of research.

While it is clear that LAIs and other long-acting treatment regimens will not become the mainstay of HIV treatment for years to come, they certainly have the potential to someday revolutionize HIV management. In the absence of an HIV cure, and with appropriate planning and support, LAIs are well-positioned to redefine HIV treatment regimens, define the next frontier of HIV medicine, and save and prolong the lives of millions. How quickly they advance from concept to game-changer is up to us.
References


49. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm895.htm


